Drugs / YYB-103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05540873 | Jul 2022 → Feb 2024 | malignant glioma | CellabMED | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YYB-103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05540873 ↗ |
| Modality | Cell therapy | “IL13Rα2 targeted CAR-T cell” NCT05540873 ↗ |
| Route | Intravenous | “Administration method: intravenous infusion” NCT05540873 ↗ |